Bullish
H.C. Wainwright Remains a Buy on Iovance Biotherapeutics (IOVA)
H.C. Wainwright reiterated a Buy rating on Iovance Biotherapeutics (IOVA) with a $9 price target, citing two positive developments for its lead therap...